Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term ...

Hims & Hers Health ( HIMS +1.45%) continues to be a volatile stock. The stock's value has been cut in half over the past year ...

Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best ...

Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.

May 11 (Reuters) - Hims & Hers Health raised its 2026 revenue forecast on Monday, betting on increased sales for its ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic ...

Hims & Hers (NYSE: HIMS) is in the middle of a very public dispute with Novo Nordisk (NYSE: NVO). However, this fight isn't likely to derail Hims & Hers long term. Here's why this direct-to-consumer ...

Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...

As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...

CHONGQING, CHINA - JULY 30: In this photo illustration, a smartphone displays the logo of Hims & Hers Health Inc. (NYSE: HIMS), a telehealth company offering personal wellness and healthcare products ...

The company is profitable, and its subscriber base is growing. Hims & Hers makes and sells drugs. That's not remotely unusual. The key difference is the way the company interacts with its customers, ...